ICON Public Limited Company (ICLR) Forms $119.29 Double Top; Cara Therapeutics, Inc. (CARA) Covered By 10 Bulls

April 17, 2018 - By Migdalia James

Cara Therapeutics, Inc. (NASDAQ:CARA) Logo

ICON Public Limited Company (ICLR) formed double top with $127.64 target or 7.00% above today’s $119.29 share price. ICON Public Limited Company (ICLR) has $6.45 billion valuation. The stock decreased 0.43% or $0.51 during the last trading session, reaching $119.29. About 189,314 shares traded. ICON Public Limited Company (NASDAQ:ICLR) has risen 52.69% since April 17, 2017 and is uptrending. It has outperformed by 41.14% the S&P500.

Among 10 analysts covering Cara Therapeutics (NASDAQ:CARA), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cara Therapeutics had 27 analyst reports since July 27, 2015 according to SRatingsIntel. The company was maintained on Friday, August 4 by H.C. Wainwright. Janney Capital downgraded it to “Neutral” rating and $21 target in Friday, June 30 report. Needham maintained the stock with “Buy” rating in Tuesday, October 3 report. Laidlaw maintained the shares of CARA in report on Friday, June 30 with “Buy” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, August 3 report. The firm has “Buy” rating by H.C. Wainwright given on Thursday, June 22. The stock of Cara Therapeutics, Inc. (NASDAQ:CARA) has “Buy” rating given on Wednesday, June 21 by Needham. Canaccord Genuity maintained it with “Buy” rating and $2500 target in Friday, August 4 report. Canaccord Genuity maintained it with “Buy” rating and $22.0 target in Thursday, March 15 report. Cantor Fitzgerald initiated Cara Therapeutics, Inc. (NASDAQ:CARA) on Wednesday, November 4 with “Buy” rating. See Cara Therapeutics, Inc. (NASDAQ:CARA) latest ratings:

19/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $22.0 Maintain
15/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $22.0 Maintain
12/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $22 Reinitiate
12/02/2018 Broker: Janney Capital Old Rating: Neutral New Rating: Buy Old Target: $21 Upgrade
19/01/2018 Broker: Seaport Global Rating: Buy New Target: $27 Initiates Coverage On
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $17.0 Maintain

Analysts await ICON Public Limited Company (NASDAQ:ICLR) to report earnings on May, 3 before the open. They expect $1.41 earnings per share, up 9.30% or $0.12 from last year’s $1.29 per share. ICLR’s profit will be $76.25 million for 21.15 P/E if the $1.41 EPS becomes a reality. After $1.43 actual earnings per share reported by ICON Public Limited Company for the previous quarter, Wall Street now forecasts -1.40% negative EPS growth.

Among 12 analysts covering Icon plc (NASDAQ:ICLR), 7 have Buy rating, 1 Sell and 4 Hold. Therefore 58% are positive. Icon plc has $145.0 highest and $77 lowest target. $120.55’s average target is 1.06% above currents $119.29 stock price. Icon plc had 40 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, January 10 by KeyBanc Capital Markets. Barclays Capital maintained ICON Public Limited Company (NASDAQ:ICLR) rating on Friday, October 27. Barclays Capital has “Equal-Weight” rating and $120 target. Evercore downgraded the shares of ICLR in report on Tuesday, April 3 to “In-Line” rating. The firm has “Outperform” rating given on Tuesday, June 21 by Credit Suisse. The company was maintained on Monday, September 11 by Jefferies. The stock of ICON Public Limited Company (NASDAQ:ICLR) earned “Outperform” rating by Credit Suisse on Friday, August 14. The firm has “Buy” rating given on Thursday, June 29 by Jefferies. The stock has “Buy” rating by Robert W. Baird on Thursday, June 8. Avondale initiated the stock with “Market Perform” rating in Wednesday, October 21 report. The firm earned “Mkt Underperform” rating on Thursday, June 9 by Avondale.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company has market cap of $401.44 million. It is developing product candidates that target the body's peripheral nervous system. It currently has negative earnings. The companyÂ’s lead product candidate comprises I.V.

Investors sentiment increased to 0.93 in 2017 Q4. Its up 0.08, from 0.85 in 2017Q3. It improved, as 16 investors sold Cara Therapeutics, Inc. shares while 28 reduced holdings. 21 funds opened positions while 20 raised stakes. 15.80 million shares or 11.38% less from 17.83 million shares in 2017Q3 were reported. Vanguard Grp invested in 1.22M shares or 0% of the stock. Metropolitan Life Ins invested in 0% or 8,685 shares. Alliancebernstein L P accumulated 38,600 shares. Vantage Inv Advsr Limited Liability Corp holds 1,350 shares or 0% of its portfolio. Citigroup has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Blackrock reported 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Price T Rowe Md stated it has 479,213 shares or 0% of all its holdings. Bnp Paribas Arbitrage accumulated 0% or 5,498 shares. Voya Invest Mngmt Limited Com, Georgia-based fund reported 12,316 shares. Td Asset Management has 19,200 shares for 0% of their portfolio. Dafna Management Lc owns 93,800 shares for 0.62% of their portfolio. Pnc Fincl Ser Grp holds 0% or 4,600 shares in its portfolio. Swiss Bank owns 42,300 shares. Jefferies Ltd Limited Liability Company reported 21,500 shares or 0% of all its holdings. State Of Wisconsin Investment Board reported 20,000 shares.

Since January 24, 2018, it had 0 insider purchases, and 4 insider sales for $538,560 activity. Shares for $45,060 were sold by Menzaghi Frederique Ph.D.. On Friday, February 16 CHALMERS DEREK T sold $81,000 worth of Cara Therapeutics, Inc. (NASDAQ:CARA) or 5,400 shares.

The stock decreased 1.29% or $0.16 during the last trading session, reaching $12.28. About 305,921 shares traded. Cara Therapeutics, Inc. (NASDAQ:CARA) has declined 32.45% since April 17, 2017 and is downtrending. It has underperformed by 44.00% the S&P500.

Cara Therapeutics, Inc. (NASDAQ:CARA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts